Molecular Neurobiology

, Volume 54, Issue 4, pp 2790–2800 | Cite as

Hypoxanthine Intrastriatal Administration Alters Neuroinflammatory Profile and Redox Status in Striatum of Infant and Young Adult Rats

  • Helena Biasibetti
  • Paula Pierozan
  • André Felipe Rodrigues
  • Vanusa Manfredini
  • Angela T. S. WyseEmail author


Hypoxanthine, the major oxypurine metabolite involved in purine’s salvage pathway in the brain, is accumulated in Lesch-Nyhan disease, an inborn error of metabolism of purine. The purpose of this study was to investigate the effects of hypoxanthine intrastriatal administration on infant and young adult rats submitted to stereotactic surgery. We analyzed the effect of hypoxanthine on neuroinflammatory parameters, such as cytokine levels, immunocontent of NF-κB/p65 subunit, iNOS immunocontent, nitrite levels, as well as IBA1 and GFAP immunocontent in striatum of infant and young adult rats. We also evaluate some oxidative parameters, including reactive species production, superoxide dismutase, catalase, glutathione peroxidase activities, as well as DNA damage. Wistar rats of 21 and 60 days of life underwent stereotactic surgery and were divided into two groups: control (infusion of saline 0.9 %) and hypoxanthine (10 μM). Intrastriatal administration of hypoxanthine increased IL-6 levels in striatum of both ages of rats tested, while TNF-α increased only in 21-day-old rats. Hypoxanthine also increased nuclear immunocontent of NF-κB/p65 subunit in striatum of both ages of rats. Nitrite levels were decreased in striatum of 21-day-old rats; however, the immunocontent of iNOS was increased in striatum of hypoxanthine groups. Microglial and astrocyte activation was seen by the increase in IBA1 and GFAP immunocontent, respectively, in striatum of infant rats. All oxidative parameters were altered, suggesting a strong neurotoxic hypoxanthine role on oxidative stress. According to our results, hypoxanthine intrastriatal administration increases neuroinflammatory parameters perhaps through oxidative misbalance, suggesting that this process may be involved, at least in part, to neurological disorders found in patients with Lesch-Nyhan disease.


Hypoxanthine Neuroinflammation Microglial and astrocyte markers DNA damage Lesch-Nyhan disease 



This work was supported in part by grants from Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq-Brazil).

Compliance with Ethical Standards

Conflict of Interests

The authors declare that they have no conflict of interest.


  1. 1.
    Lesch M, Nyhan WL (1964) A familial disorder of uric acid metabolism and central nervous system function. Am J Med 36:561–570CrossRefPubMedGoogle Scholar
  2. 2.
    Nyhan WL (1978) Ataxia and disorders of purine metabolism: defects in hypoxanthine guanine phosphoribosyl transferase and clinical ataxia. Adv Neurol 21:279–287PubMedGoogle Scholar
  3. 3.
    Jinnah H, Friedmann T (2001) Lesch-Nyhan disease and its variants. In: Scriver C, Beaudet A, Sly W, Valle D (eds) Metabolic molecular bases of inherited disease. Mc Graw-Hill, New York, pp 2537–2569Google Scholar
  4. 4.
    Jinnah HA, Hess EJ, Wilson MC, Gage FH, Friedmann T (1992) Localization of hypoxanthine-guanine phosphoribosyltransferase mRNA in the mouse brain by in situ hybridization. Mol Cell Neurosci 3:64–78. doi: 10.1016/1044-7431(92)90010-Y CrossRefPubMedGoogle Scholar
  5. 5.
    Visser J, Bär P, Jinnah H (2000) Lesch–Nyhan disease and the basal ganglia. Brain Res Rev 32:449–475. doi: 10.1016/S0165-0173(99)00094-6 CrossRefPubMedGoogle Scholar
  6. 6.
    Harkness RA, McCreanor GM, Watts RWE (1988) Lesch-Nyhan syndrome and its pathogenesis: purine concentrations in plasma and urine with metabolite profiles in CSF. J Inherit Metab Dis 11:239–252. doi: 10.1007/BF01800365 CrossRefPubMedGoogle Scholar
  7. 7.
    Rosenbloom FM, Kelley WN, Miller J, Henderson JF, Seegmiller JE (1967) Inherited disorder of purine metabolism. Correlation between central nervous system dysfunction and biochemical defects. JAMA 202:175–177CrossRefPubMedGoogle Scholar
  8. 8.
    Schultz V, Lowenstein JM (1976) Purine nucleotide cycle. Evidence for the occurrence of the cycle in brain. J Biol Chem 251:485–492PubMedGoogle Scholar
  9. 9.
    Schretlen DJ, Varvaris M, Vannorsdall TD, Gordon B, Harris JC, Jinnah HA (2015) Brain white matter volume abnormalities in Lesch-Nyhan disease and its variants. Neurology 84:190–196. doi: 10.1212/WNL.0000000000001128 CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Göttle M, Prudente CN, Fu R, Sutcliffe D, Pang H, Cooper D, Veledar E, Glass JD, Gearing M, Visser JE, Jinnah HA (2014) Loss of dopamine phenotype among midbrain neurons in Lesch-Nyhan disease. Ann Neurol. doi: 10.1002/ana.24191Google Scholar
  11. 11.
    Jinnah HA, Sabina RL, Van Den Berghe G (2013) Metabolic disorders of purine metabolism affecting the nervous system. Handb Clin Neurol 113:1827–1836. doi: 10.1016/B978-0-444-59565-2.00052-6 CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Torres RJ, Puig JG (2008) The diagnosis of HPRT deficiency in the 21st century. Nucleosides Nucleotides Nucleic Acids 27:564–569. doi: 10.1080/15257770802135778 CrossRefPubMedGoogle Scholar
  13. 13.
    Das Sarma J (2014) Microglia-mediated neuroinflammation is an amplifier of virus-induced neuropathology. J Neurovirol 20:122–136. doi: 10.1007/s13365-013-0188-4 CrossRefPubMedGoogle Scholar
  14. 14.
    Ghirnikar RS, Lee YL, Eng LF (1998) Inflammation in traumatic brain injury: role of cytokines and chemokines. Neurochem Res 23:329–340CrossRefPubMedGoogle Scholar
  15. 15.
    Dallot E, Méhats C, Oger S, Leroy M-J, Breuiller-Fouché M (2005) A role for PKCzeta in the LPS-induced translocation NF-kappaB p65 subunit in cultured myometrial cells. Biochimie 87:513–521. doi: 10.1016/j.biochi.2005.02.009 CrossRefPubMedGoogle Scholar
  16. 16.
    Halliwell B (2007) Biochemistry of oxidative stress. Biochem Soc Trans 35:1147–1150. doi: 10.1042/BST0351147 CrossRefPubMedGoogle Scholar
  17. 17.
    Oliveira PJ, Rolo AP, Palmeira CM, Moreno AJ (2001) Carvedilol reduces mitochondrial damage induced by hypoxanthine/xanthine oxidase: relevance to hypoxia/reoxygenation injury. Cardiovasc Toxicol 1:205–213CrossRefPubMedGoogle Scholar
  18. 18.
    Bavaresco CS, Chiarani F, Wannmacher CMD, Netto CA, De Wyse ATS (2007) Intrastriatal hypoxanthine reduces Na+, K+-ATPase activity and induces oxidative stress in the rats. Metab Brain Dis 22:1–11. doi: 10.1007/s11011-006-9037-y CrossRefPubMedGoogle Scholar
  19. 19.
    Bavaresco CS, Zugno AI, Tagliari B, Wannmacher CMD, Wajner M, Wyse ATS (2004) Inhibition of Na+, K+-ATPase activity in rat striatum by the metabolites accumulated in Lesch-Nyhan disease. Int J Dev Neurosci 22:11–17. doi: 10.1016/j.ijdevneu.2003.11.002 CrossRefPubMedGoogle Scholar
  20. 20.
    Engin E, Treit D (2007) The role of hippocampus in anxiety: intracerebral infusion studies. Behav Pharmacol 18:365–374. doi: 10.1097/FBP.0b013e3282de7929 CrossRefPubMedGoogle Scholar
  21. 21.
    Zugno AI, Scherer EBS, Mattos C, Ribeiro CAJ, Wannmacher CMD, Wajner M, Wyse ATS (2007) Evidence that the inhibitory effects of guanidinoacetate on the activities of the respiratory chain, Na+, K+-ATPase and creatine kinase can be differentially prevented by taurine and vitamins E and C administration in rat striatum in vivo. Biochim Biophys Acta 1772:563–569. doi: 10.1016/j.bbadis.2007.02.005 CrossRefPubMedGoogle Scholar
  22. 22.
    Tsenov G, Mátéffyová A, Mares P, Otáhal J, Kubová H (2007) Intrahippocampal injection of endothelin-1: a new model of ischemia-induced seizures in immature rats. Epilepsia 48(Suppl 5):7–13. doi: 10.1111/j.1528-1167.2007.01282.x CrossRefPubMedGoogle Scholar
  23. 23.
    Paxinos G, Watson C (2006) The rat brain in stereotaxic coordinates, sixth edition. Acad Press 170:547–612. doi: 10.1016/0143-4179(83)90049-5 Google Scholar
  24. 24.
    Ozden S, Isenmann S (2004) Neuroprotective properties of different anesthetics on axotomized rat retinal ganglion cells in vivo. J Neurotrauma 21:73–82. doi: 10.1089/089771504772695968 CrossRefPubMedGoogle Scholar
  25. 25.
    Puig JG, Jimenez ML, Mateos FA, Fox IH (1989) Adenine nucleotide turnover in hypoxanthine-guanine phosphoribosyl-transferase deficiency: evidence for an increased contribution of purine biosynthesis de novo. Metabolism 38:410–418CrossRefPubMedGoogle Scholar
  26. 26.
    Scherer EBS, Loureiro SO, Vuaden FC, da Cunha AA, Schmitz F, Kolling J, Savio LEB, Bogo MR et al (2014) Mild hyperhomocysteinemia increases brain acetylcholinesterase and proinflammatory cytokine levels in different tissues. Mol Neurobiol 50:589–596. doi: 10.1007/s12035-014-8660-6 CrossRefPubMedGoogle Scholar
  27. 27.
    Da Cunha MJ, da Cunha AA, Loureiro SO, Machado FR, Schmitz F, Kolling J, Marques EP, Wyse ATS (2015) Experimental lung injury promotes changes in oxidative/nitrative status and inflammatory markers in cerebral cortex of rats. Mol Neurobiol 52:1590–1600. doi: 10.1007/s12035-014-8961-9 CrossRefPubMedGoogle Scholar
  28. 28.
    Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR (1982) Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal Biochem 126:131–138CrossRefPubMedGoogle Scholar
  29. 29.
    Da Cunha AA, Ferreira AGK, Loureiro SO, da Cunha MJ, Schmitz F, Netto CA, Wyse ATS (2012) Chronic hyperhomocysteinemia increases inflammatory markers in hippocampus and serum of rats. Neurochem Res 37:1660–1669. doi: 10.1007/s11064-012-0769-2 CrossRefPubMedGoogle Scholar
  30. 30.
    Schmitz F, Pierozan P, Rodrigues AF, Biasibetti H, Coelho DM, Mussulini BH, Pereira MSL, Parisi MM, Barbé-Tuana F, de Oliveira DL, Vargas CR, Wyse ATS (2015) Chronic treatment with a clinically relevant dose of methylphenidate increases glutamate levels in cerebrospinal fluid and impairs glutamatergic homeostasis in prefrontal cortex of juvenile rats. Mol Neurobiol. doi: 10.1007/s12035-015-9219-xGoogle Scholar
  31. 31.
    LeBel CP, Ali SF, McKee M, Bondy SC (1990) Organometal-induced increases in oxygen reactive species: The potential of 2′,7′-dichlorofluorescin diacetate as an index of neurotoxic damage. Toxicol Appl Pharmacol 104:17–24. doi: 10.1016/0041-008X(90)90278-3 CrossRefPubMedGoogle Scholar
  32. 32.
    Marklund S, Marklund G (1974) Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur J Biochem 47:469–474. doi: 10.1111/j.1432-1033.1974.tb03714.x CrossRefPubMedGoogle Scholar
  33. 33.
    Aebi H (1984) Catalase in vitro. Methods Enzymol 105:121–126. doi: 10.1016/S0076-6879(84)05016-3 CrossRefPubMedGoogle Scholar
  34. 34.
    Wendel A (1981) Glutathione peroxidase. Methods Enzymol 77:325–533. doi: 10.1016/S0076-6879(81)77046-0 CrossRefPubMedGoogle Scholar
  35. 35.
    Singh NP, McCoy MT, Tice RR, Schneider EL (1988) A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res 175:184–191. doi: 10.1016/0014-4827(88)90265-0 CrossRefPubMedGoogle Scholar
  36. 36.
    Tice RR, Agurell E, Anderson D, Burlinson B, Hartmann A, Kobayashi H, Miyamae Y, Rojas E et al (2000) Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environ Mol Mutagen 35:206–221CrossRefPubMedGoogle Scholar
  37. 37.
    Hartmann A, Agurell E, Beevers C, Brendler-Schwaab S, Burlinson B, Clay P, Collins A, Smith A et al (2003) Recommendations for conducting the in vivo alkaline comet assay. 4th International Comet Assay Workshop. Mutagenesis 18:45–51CrossRefPubMedGoogle Scholar
  38. 38.
    Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–275PubMedGoogle Scholar
  39. 39.
    Li Q, Verma IM (2002) NF-kappaB regulation in the immune system. Nat Rev Immunol 2:725–734. doi: 10.1038/nri910 CrossRefPubMedGoogle Scholar
  40. 40.
    Morris KR, Lutz RD, Choi H-S, Kamitani T, Chmura K, Chan ED (2003) Role of the NF-kappaB signaling pathway and kappaB cis-regulatory elements on the IRF-1 and iNOS promoter regions in mycobacterial lipoarabinomannan induction of nitric oxide. Infect Immun 71:1442–1452CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Guo G, Bhat NR (2006) Hypoxia/reoxygenation differentially modulates NF-kappaB activation and iNOS expression in astrocytes and microglia. Antioxid Redox Signal 8:911–918. doi: 10.1089/ars.2006.8.911 CrossRefPubMedGoogle Scholar
  42. 42.
    Bavaresco CS, Chiarani F, Kolling J, Netto CA, de Souza Wyse AT (2008) Biochemical effects of pretreatment with vitamins E and C in rats submitted to intrastriatal hypoxanthine administration. Neurochem Int 52:1276–1283. doi: 10.1016/j.neuint.2008.01.008 CrossRefPubMedGoogle Scholar
  43. 43.
    Torres RJ, Puig JG (2015) Hypoxanthine deregulates genes involved in early neuronal development. Implications in Lesch-Nyhan disease pathogenesis. J Inherit Metab Dis. doi: 10.1007/s10545-015-9854-4Google Scholar
  44. 44.
    Lucas S-M, Rothwell NJ, Gibson RM (2006) The role of inflammation in CNS injury and disease. Br J Pharmacol 147(Suppl):S232–S240. doi: 10.1038/sj.bjp.0706400 PubMedPubMedCentralGoogle Scholar
  45. 45.
    Beal MF (1995) Aging, energy, and oxidative stress in neurodegenerative diseases. Ann Neurol 38:357–366. doi: 10.1002/ana.410380304 CrossRefPubMedGoogle Scholar
  46. 46.
    Tak PP, Firestein GS (2001) NF-kappaB: a key role in inflammatory diseases. J Clin Invest 107:7–11. doi: 10.1172/JCI11830 CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Libermann TA, Baltimore D (1990) Activation of interleukin-6 gene expression through the NF-kappa B transcription factor. Mol Cell Biol 10:2327–2334CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Shimizu Y, van Seventer GA, Horgan KJ, Shaw S (1990) Costimulation of proliferative responses of resting CD4+ T cells by the interaction of VLA-4 and VLA-5 with fibronectin or VLA-6 with laminin. J Immunol 145:59–67PubMedGoogle Scholar
  49. 49.
    Son Y-H, Jeong Y-T, Lee K-A, Choi K-H, Kim S-M, Rhim B-Y, Kim K (2008) Roles of MAPK and NF-kappaB in interleukin-6 induction by lipopolysaccharide in vascular smooth muscle cells. J Cardiovasc Pharmacol 51:71–77. doi: 10.1097/FJC.0b013e31815bd23d CrossRefPubMedGoogle Scholar
  50. 50.
    Shakhov AN, Kuprash DV, Azizov MM, Jongeneel CV, Nedospasov SA (1990) Structural analysis of the rabbit TNF locus, containing the genes encoding TNF-beta (lymphotoxin) and TNF-alpha (tumor necrosis factor). Gene 95:215–221CrossRefPubMedGoogle Scholar
  51. 51.
    Shakhov AN, Collart MA, Vassalli P, Nedospasov SA, Jongeneel CV (1990) Kappa B-type enhancers are involved in lipopolysaccharide-mediated transcriptional activation of the tumor necrosis factor alpha gene in primary macrophages. J Exp Med 171:35–47CrossRefPubMedGoogle Scholar
  52. 52.
    Hughes JE, Srinivasan S, Lynch KR, Proia RL, Ferdek P, Hedrick CC (2008) Sphingosine-1-phosphate induces an antiinflammatory phenotype in macrophages. Circ Res 102:950–958. doi: 10.1161/CIRCRESAHA.107.170779 CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Gudbjörnsson B, Zak A, Niklasson F, Hällgren R (1991) Hypoxanthine, xanthine, and urate in synovial fluid from patients with inflammatory arthritides. Ann Rheum Dis 50:669–672CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Knowles RG, Moncada S (1994) Nitric oxide synthases in mammals. Biochem J 298(Pt 2):249–258CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Lechner M, Lirk P, Rieder J (2005) Inducible nitric oxide synthase (iNOS) in tumor biology: the two sides of the same coin. Semin Cancer Biol 15:277–289. doi: 10.1016/j.semcancer.2005.04.004 CrossRefPubMedGoogle Scholar
  56. 56.
    Moncada S (1993) The L-arginine: nitric oxide pathway, cellular transduction and immunological roles. Adv Second Messenger Phosphoprotein Res 28:97–99PubMedGoogle Scholar
  57. 57.
    Brown GC, Neher JJ (2010) Inflammatory neurodegeneration and mechanisms of microglial killing of neurons. Mol Neurobiol 41:242–247. doi: 10.1007/s12035-010-8105-9 CrossRefPubMedGoogle Scholar
  58. 58.
    Borutaite V, Budriunaite A, Brown GC (2000) Reversal of nitric oxide-, peroxynitrite- and S-nitrosothiol-induced inhibition of mitochondrial respiration or complex I activity by light and thiols. Biochim Biophys Acta 1459:405–412CrossRefPubMedGoogle Scholar
  59. 59.
    Ribeiro BMM, do Carmo MRS, Freire RS, Rocha NFM, Borella VCM, de Menezes AT, Monte AS, Gomes PXL et al (2013) Evidences for a progressive microglial activation and increase in iNOS expression in rats submitted to a neurodevelopmental model of schizophrenia: reversal by clozapine. Schizophr Res 151:12–19. doi: 10.1016/j.schres.2013.10.040 CrossRefPubMedGoogle Scholar
  60. 60.
    Xu L, He D, Bai Y (2015) Microglia-mediated inflammation and neurodegenerative disease. Mol Neurobiol. doi: 10.1007/s12035-015-9593-4Google Scholar
  61. 61.
    Magni P, Ruscica M, Dozio E, Rizzi E, Beretta G, Maffei Facino R (2012) Parthenolide inhibits the LPS-induced secretion of IL-6 and TNF-α and NF-κB nuclear translocation in BV-2 microglia. Phytother Res 26:1405–1409. doi: 10.1002/ptr.3732 CrossRefPubMedGoogle Scholar
  62. 62.
    Takeuchi H, Jin S, Wang J, Zhang G, Kawanokuchi J, Kuno R, Sonobe Y, Mizuno T et al (2006) Tumor necrosis factor-alpha induces neurotoxicity via glutamate release from hemichannels of activated microglia in an autocrine manner. J Biol Chem 281:21362–21368. doi: 10.1074/jbc.M600504200 CrossRefPubMedGoogle Scholar
  63. 63.
    Guizzetti M, Zhang X, Goeke C, Gavin DP (2014) Glia and neurodevelopment: focus on fetal alcohol spectrum disorders. Front Pediatr 2:123–135. doi: 10.3389/fped.2014.00123 CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    Sofroniew MV (2009) Molecular dissection of reactive astrogliosis and glial scar formation. Trends Neurosci 32:638–647. doi: 10.1016/j.tins.2009.08.002 CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    Pekny M, Nilsson M (2005) Astrocyte activation and reactive gliosis. Glia 50:427–434. doi: 10.1002/glia.20207 CrossRefPubMedGoogle Scholar
  66. 66.
    Li N, Karin M (1999) Is NF-{kappa}B the sensor of oxidative stress? FASEB J 13:1137–1143PubMedGoogle Scholar
  67. 67.
    Marnett LJ (2000) Oxyradicals and DNA damage. Carcinogenesis 21:361–370. doi: 10.1093/carcin/21.3.361 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Helena Biasibetti
    • 1
  • Paula Pierozan
    • 1
  • André Felipe Rodrigues
    • 1
  • Vanusa Manfredini
    • 2
  • Angela T. S. Wyse
    • 1
    • 3
    Email author
  1. 1.Programa de Pós-Graduação em Ciências Biológicas: Bioquímica, ICBSUFRGSPorto AlegreBrazil
  2. 2.Universidade Federal do PampaUruguaianaBrazil
  3. 3.Laboratório de Neuroproteção e Doenças Neurometabólicas. Departamento de Bioquímica, ICBSUniversidade Federal do Rio Grande do SulPorto AlegreBrazil

Personalised recommendations